Introduction Coherent Biopharma Suzhou Co. Ltd. is a business that specializes in producing biological products. It was established by Bao Hua Huang on March 3rd, 2016 and has its headquarters located in Suzhou, China. |
Disease Domain | Count |
---|---|
Neoplasms | 9 |
Endocrinology and Metabolic Disease | 2 |
Top 5 Drug Type | Count |
---|---|
Peptide drug conjugates | 3 |
Small molecule-drug conjugates | 2 |
Monoclonal antibody | 1 |
Unknown | 1 |
Proteolysis-targeting chimeras | 1 |
Top 5 Target | Count |
---|---|
FOLR1 x TRPV6 | 2 |
FOLR1 x TRPV6 x Tubulin | 1 |
CLDN18.2(Claudin 18.2) | 1 |
TOP(Topoisomerases) | 1 |
EGFR x c-Met | 1 |
Target |
Mechanism FOLR1 agonists [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2/3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism FOLR1 antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism FOLR1 antagonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date16 Oct 2023 |
Sponsor / Collaborator |
Start Date14 Aug 2023 |
Sponsor / Collaborator |
Start Date14 Mar 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
CBP-1008 ( FOLR1 x TRPV6 x Tubulin ) | Breast Cancer More | Phase 3 Clinical |
CBP-1019 ( FOLR1 x TRPV6 ) | Esophageal Carcinoma More | Phase 2 Clinical |
CBP-1018 ( FOLR1 x TRPV6 ) | Bone metastases More | Phase 1 |
CBP-8088 | Neoplasms More | IND Application |
CBP-1203 | Solid tumor More | Preclinical |